Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Therapy With Anti-PD-1 Antibody in Unresectable Pancreatic Cancer
NCT03374293Phase 2Unknown
- Sponsor
- Hangzhou Cancer Hospital
- Start
- Dec 2017
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in pancreatic cancer (PC), sponsored by Hangzhou Cancer Hospital. Primary endpoint: Local Control at 2 years. Status: unknown.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03374293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374293.